Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Luteinizing hormone-releasing hormone agonists, used in advanced prostate cancer, can cause an initial testosterone surge and may inadequately suppress follicle-stimulating hormone, potentially promoting tumor growth. Injectable gonadotropin-releasing hormone (GnRH) antagonists avoid this surge but have drawbacks like injection-site reactions and monthly dosing. Relugolix, an oral GnRH antagonist, offers rapid testosterone suppression without flare and reduced cardiovascular risks. We report a 72-year-old man with suspected metastatic prostate cancer, presenting with severe neuritic pain and lower limb weakness. Relugolix, started before biopsy along with zoledronic acid and steroids, led to symptom relief within 24 h. This case supports Relugolix's utility in urgent hormone-sensitive metastatic prostate cancer care.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4103/aam.aam_192_25 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhancing Readability of Lay Abstracts and Summaries for Urologic Oncology Literature Using Generative Artificial Intelligence: BRIDGE-AI 6 Randomized Controlled Trial.
JCO Clin Cancer Inform
September 2025
USC Institute of Urology and Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Purpose: To evaluate a generative artificial intelligence (GAI) framework for creating readable lay abstracts and summaries (LASs) of urologic oncology research, while maintaining accuracy, completeness, and clarity, for the purpose of assessing their comprehension and perception among patients and caregivers.
Methods: Forty original abstracts (OAs) on prostate, bladder, kidney, and testis cancers from leading journals were selected. LASs were generated using a free GAI tool, with three versions per abstract for consistency.
Genomic Risk Classifiers in Localized Prostate Cancer: Precise but Not Standardized.
JCO Precis Oncol
September 2025
Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA.
Super Responder of 177Lu-PSMA-617 PSMA Therapy in Patient With End-Stage Renal Disease on Hemodialysis.
Clin Nucl Med
September 2025
Department of Radiology and Nuclear Medicine, Comprehensive Cancer Care and Research Center (SQCCCRC), University Medical City, Muscat, Oman.
PSMA-targeted radioligand therapies with 177Lu-PSMA-617 have shown promising response rates with favorable toxicity in patients with metastasized castration-resistant prostate cancer. We report a case of a 72-year-old man with metastatic castration-resistant prostate cancer having comorbidities of DM, HTN, and end-stage renal disease (ESRD) on regular hemodialysis. The patient received 2 doses of 7.
View Article and Find Full Text PDFDiscovery of -(thiazol-2-yl) Furanamide Derivatives as Potent Orally Efficacious AR Antagonists with Low BBB Permeability.
J Med Chem
September 2025
State Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China.
Resistance-conferring mutations in the androgen receptor (AR) ligand-binding pocket (LBP) compromise the effectiveness of clinically approved orthosteric AR antagonists. Targeting the dimerization interface pocket (DIP) of AR presents a promising therapeutic approach. In this study, we report the design and optimization of -(thiazol-2-yl) furanamide derivatives as novel AR DIP antagonists, among which was the most promising candidate.
View Article and Find Full Text PDFBiparametric vs Multiparametric MRI for Prostate Cancer Diagnosis: The PRIME Diagnostic Clinical Trial.
JAMA
September 2025
Division of Surgery and Interventional Science, UCL, London, United Kingdom.
Importance: Multiparametric magnetic resonance imaging (MRI), with or without prostate biopsy, has become the standard of care for diagnosing clinically significant prostate cancer. Resource capacity limits widespread adoption. Biparametric MRI, which omits the gadolinium contrast sequence, is a shorter and cheaper alternative offering time-saving capacity gains for health systems globally.
View Article and Find Full Text PDF